MapLight Therapeutics

MPLTPhase 2

MapLight Therapeutics is focused on transforming the treatment of brain disorders by developing precision medicines that target specific dysfunctional neural circuits. The company's MAP (Molecular and Anatomical Phenotyping) platform integrates advanced neuroscience tools to deconstruct complex behaviors and identify novel therapeutic targets. With a lead program in Phase 2 for autism spectrum disorder and a pipeline of preclinical candidates, MapLight is advancing a new generation of neuropsychiatric drugs. The company went public in 2024 and is positioned to address significant unmet needs in neurology and psychiatry.

Market Cap

$796.8M

Employees

50-100

Focus

Biotech

MPLT · Stock Price

USD 17.560.78 (-4.25%)

Historical price data

AI Company Overview

Technology Platform

The MAP (Molecular and Anatomical Phenotyping) platform integrates circuit neuroscience, behavioral analysis, and computational biology to identify and validate novel targets for neuropsychiatric disorders based on their role in specific dysfunctional neural circuits.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
ML-004 (IR)/(ER) tablet	Autism Spectrum Disorder	Phase 2
Placebo + ML-007C-MA BID + ML-007C-MA QD	Schizophrenia	Phase 2
ML-004 (IR)/(ER) tablet + ML-004 Placebo	Autism Spectrum Disorder	Phase 2
ML-007C-MA	Psychosis Associated With Alzheimer's Disease	Phase 2
ML-007C-MA	Schizophrenia	Phase 2

Opportunities

MapLight has significant growth opportunities through expansion of its lead candidate ML-007 into additional neuropsychiatric indications with shared circuit dysfunction, development of its preclinical pipeline for major depressive disorder and Alzheimer's disease, and potential platform partnerships with larger pharmaceutical companies.

The company's circuit-based approach could enable a new generation of precision neurotherapeutics across multiple disorders.

Risk Factors

Key risks include high clinical failure rates typical of CNS drug development, regulatory challenges in establishing novel endpoints for symptom-specific treatments, intense competition from larger pharmaceutical companies, and the need for additional financing if clinical trials are delayed or expanded.

The complexity of translating circuit neuroscience into effective human therapies presents significant scientific and development risks.

Competitive Landscape

MapLight faces competition from both large pharmaceutical companies (Roche, Karuna Therapeutics, Intra-Cellular Therapies) and biotechnology firms (Yamo, Neuren, Minerva) developing treatments for neuropsychiatric disorders. The company differentiates through its circuit-specific targeting approach, strong preclinical validation combining human genetics and neuroscience, and focus on transdiagnostic symptom domains rather than traditional diagnostic categories.

Publications

Pipeline